What Will the Pharma Industry Look Like in 5 Years?
There are an estimated 724 projects in development from the top 50
pharmaceutical companies. Together, they have the potential to add billions
in value to the current pharmaceutical market in the next five years. What
types of drugs are companies developing and what will be the impact of these
products on the marketplace and key competitors? In this report, Kalorama
Information has analyzed the late-stage R&D pipeline of the 50 top companies
in pharmaceuticals -- the companies that produce the lion's share of industry
revenues.
Coverage of the 50 Leading Companies
This report takes a look at the pipeline of the following companies. The top
companies include pharmaceutical companies that are considered to be the top
50 companies worldwide in terms of generated revenues, these include:
Abbott Laboratories
Actelion
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen IDEC
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene Corp.
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly & Co.
Forest
Gilead Sciences
GlaxoSmithKline
Grifols SA
Hospira
Johnson & Johnson
Kyowa Kirin
Lundbeck
Menarini
Merck
Merck KGaA
Mitsubishi Tanabe Pharma
Mylan
Novartis
Novo Nordisk
Ono Pharmaceutical Co.
Otsuka Pharmaceutical
Pfizer
Purdue Pharma
Reckitt Benckiser
Roche
Sanofi
Santen Pharmaceuticals
Servier
Shionogi
Shire
Taisho Pharmacueitcal
Takeda
TEVA
UCB
Valeant Pharmaceuticals
Warner Chilcott
Watson
While the report looks at the entire pipeline to 2015, a key focus of the
report is the increasing role of biopharmaceutical products. The growing
interest in biotechnology development has transitioned the pharmaceutical
industry to biopharmaceuticals in less than a decade. Companies such as
Pfizer, Merck and Novartis have been unable to ignore the benefits of
investing in biotechnology and have focused on a pipeline in this direction
through strategic acquisitions and partnerships with biotech companies and/or
through their own in-house research efforts.
Pipeline Analysis, Key Trends, Market Forecasts
This Kalorama Information market research report captures these trends,
extracting sales for all pharmaceutical and biopharmaceutical products
(excluding prophylactic vaccines and OTC products) and providing estimates and
forecasts of the world biopharma market.
As part of its coverage, the report provides the following:
Company Analysis
Pipeline Snapshot: Top 20 Companies
Market Trends and Value
Evaluating Changes in 2011 Market Value
The Traditional Pharmaceutical Market
Biotechnology Market Facts and Forecast
For the purpose of this study, Kalorama Information has extracted sales for
human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals
and products; diagnostics; devices; chemicals; agriculture; and animal health.
These are areas where many of these companies also compete with significant
market shares.
The industry has struggled in recent years but many observers see
biopharmaceutical as the key to continued success for market leaders.
Biopharmaceuticals are defined as any substance produced by natural organisms
or recombinant techniques consisting of proteins and other products derived
from living organisms for the treatment or management of diseases or injuries.
Biopharmaceuticals are created through fermentation, recombinant DNA
technology, and other bioprocesses. The complex nature of biopharmaceuticals
and the growing interest in development of these products has resulted in a
flood of new issues affecting the already complicated healthcare market. There
are a number of issues and trends which are experienced by the healthcare
industry as a whole and others which are unique to biopharmaceuticals, their
development and commercialization.
Issues and Trends discussed in this report include:
Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Biosimilar Development
Aging Populations
Mergers, Acquisitions, and Collaborations
Contributors to R&D Success
R&D Spending Trends
The Role of Contract Research Organizations
Sustainability in a Changing Pharmaceutical Industry
Table of Contents
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Potential Market Opportunity
Issues and Trends Affecting Market
Leading Companies
CHAPTER TWO: INTRODUCTION
Global Pharmaceutical Market
Pharmaceutical Research & Development Overview
Expanded Options in Treating Diseases
CHAPTER THREE: ISSUES AND TRENDS
Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Pediatric Extensions
Biopharmaceutical Industry - Biosimilar (Biogeneric) Development and
Exclusivity Legislation
Aging Population
Mergers, Acquisitions, and Collaborations
Contributors To R&D Success
R&D Spending
The Role of Contract Research Organization
Sustainability in a Changing Pharmaceutical Industry
CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS
Introduction
Pfizer, Inc.
Overview
Financial Performance and Investments
Late Stage Pipeline
Merck & Co., Inc.
Overview
Financial Performance and Investments
Late Stage Pipeline
Novartis
Overview
Financial Performance and Investments
Late Stage Pipeline
Sanofi
Overview
Financial Performance and Investments
Late Stage Pipeline
Roche Ltd.
Overview
Financial Performance and Investments
Late Stage Pipeline
GlaxoSmithKline plc
Overview
Financial Performance and Investments
Late Stage Pipeline
AstraZeneca plc
Overview
Financial Performance and Investments
Late Stage Pipeline
Johnson & Johnson
Overview
Financial Performance and Investments
Late Stage Pipeline
Eli Lilly & Company
Overview
Financial Performance and Investments
Late Stage Pipeline
Abbott Laboratories
Overview
Financial Performance and Investments
Late Stage Pipeline
Bristol-Myers Squibb Company
Overview
Financial Performance and Investments
Late Stage Pipeline
Takeda Pharmaceutical Co., Ltd.
Overview
Financial Performance and Investments
Late Stage Pipeline
TEVA Pharmaceutical Industries, Ltd.
Overview
Financial Performance and Investments
Late Stage Pipeline
Amgen, Inc.
Overview
Financial Performance and Investments
Late Stage Pipeline
Boehringer Ingelheim GmbH
Overview
Financial Performance and Investments
Late Stage Pipeline
Bayer AG
Overview
Financial Performance and Investments
Late Stage Pipeline
Novo Nordis
Overview
Financial Performance and Investments
Late Stage Pipeline
Astellas
Overview
Financial Performance and Investments
Late Stage Pipeline
Daiichi Sankyo
Overview
Financial Performance and Investmen
Late Stage Pipeline
Otsuka
Overview
Financial Performance and Investments
Late Stage Pipeline
CHAPTER FIVE: COMPANIES OF INTEREST
Introduction
Merck KGaA
Late Stage Pipeline
Gilead Sciences
Late Stage Pipeline
Eisai
Late Stage Pipeline
Mylan
Pipeline
Baxter International
Pipeline
Servier, Les Laboratories
Pipeline
Celgene Corporation
Late Stage Pipeline
Mitsubishi Tanabe
Late Stage Pipeline
Allergan
Late Stage Pipeline
Forest Laboratories
Late Stage Pipeline
CSL Limited
Late Stage Pipeline
UCB SA
Late Stage Pipeline
Dainippon Sumitomo Pharma, Co., Ltd.
Late Stage Pipeline
Shire
Late Stage Pipeline
Biogen Idec
Late Stage Pipeline
Watson
Pipeline
Hospira
Late Stage Pipeline
Lundbeck A/S
Late Stage Pipeline
Kyowa Kirin
Late Stage Pipeline
Warner Chilcott plc
Late Stage Pipeline
Menarini Group
Late Stage Pipeline
Valeant Pharmaceuticals
Late Stage Pipeline
Purdue Pharma
Late Stage Pipeline
Grifols SA
Late Stage Pipeline
Shionogi & Co., Ltd.
Late Stage Pipeline
Actelion
Late Stage Pipeline
Ono Pharmaceutical Co.
Late Stage Pipeline
Santen Pharmaceutical Co.
Late Stage Pipeline
Reckitt Benckiser
Late Stage Pipeline
Taisho Pharmaceutical Co.
Late Stage Pipeline
CHAPTER SIX: MARKET FORECAST
Overview
Company Analysis
Pipeline Snapshot: Top 20 Companies
Market Trends and Value
Evaluating Changes in 2011 Market Value
Market Forecast
The Traditional Biotechnology Market
Biotechnology Market Facts and Forecast
APPENDIX: LIST OF COMPANIES
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: Global Pharmaceutical Market Forecast by Therapeutic Segment,
2016 - based on late stage development projects evaluated
Figure 1-1: Global Pharmaceutical Market Forecast by Therapeutic Segment,
2016 - Potential Impact from Late-Stage Development
CHAPTER TWO: INTRODUCTION
Table 2-1: Total Healthcare Expenditures as a Percent of GDP by Country
1990, 2000 and 2009
Figure 2-1: Total Healthcare Expenditures as a Percent of GDP by Country
1990, 2000, and 2009
Table 2-2: Phases of Clinical Drug Development
Table 2-3: Components of a Clinical Trial
Figure 2-2: Biotechnology Approvals by Year Range (FDA)
CHAPTER THREE: ISSUES AND TRENDS
Table 3-1: International Population Trend Age 65+
Table 3-2: United States Population Trend Age 65+
Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions
CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS
Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2011 Sales
Table 4-2: Pfizer's Total Company Revenue and R&D Spending 2007-2011
Figure 4-1: Pfizer's Total Company Revenue and R&D Spending 2007-2011
Table 4-3: Pfizer's Late Stage Product Pipeline
Figure 4-2: Pfizer's Late Stage Product Pipeline by Therapeutic Area
Table 4-4: Merck's* Total Company Revenue and R&D Spending 2007-2011
Table 4-5: Merck's Late Stage Product Pipeline
Table 4-5: (continued): Merck's Late Stage Product Pipeline
Figure 4-4: Merck's Late Stage Product Pipeline by Therapeutic Area
Table 4-6: Novartis' Total Company Revenue and R&D Spending 2007-2011
Table 4-7: Novartis' Late Stage Product Pipeline
Figure 4-7: Novartis' Late Stage Product Pipeline by Therapeutic Area
Table 4-8: Sanofi's Total Company Revenue and R&D Spending 2007-2011
Table 4-9: Sanofi-Aventis' Late Stage Product Pipeline
Figure 4-8: Sanofi Aventis' Late Stage Product Pipeline by Therapeutic Area
Table 4-10: Roche's Total Company Revenue and R&D Spending 2007-2011
Table 4-11: Roche's Late Stage Product Pipeline
Figure 4-10: Roche's Late Stage Product Pipeline by Therapeutic Area
Table 4-12: GlaxoSmithKline's Total Company Revenue and R&D Spending
2007-2011
Table 4-13: GlaxoSmithKline's Late Stage Product Pipeline
Figure 4-12: GlaxoSmithKline's Late Stage Product Pipeline by Therapeutic
Area
Table 4-14: AstraZeneca's Total Company Revenue and R&D Spending 2007-2011
Table 4-15: AstraZeneca's Late Stage Product Pipeline
Figure 4-14: AstraZeneca' Late Stage Product Pipeline by Therapeutic Area
Table 4-16: Johnson & Johnson's Total Company Revenue and R&D Spending
2007-2011
Table 4-17: Johnson & Johnson's Late Stage Product Pipeline
Table 4-18: Eli Lilly's Total Company Revenue and R&D Spending 2007-2011
Table 4-19: Eli Lilly's Late Stage Product Pipeline
Figure 4-18: Eli Lilly & Co.'s Late Stage Product Pipeline by Therapeutic
Area
Table 4-20: Abbott's Total Company Revenue and R&D Spending 2007-2011
Table 4-21: Abbott's Late Stage Product Pipeline
Figure 4-20: Abbott's Late Stage Product Pipeline by Therapeutic Area
Table 4-22: Bristol-Myers Squibb's Total Company Revenue and R&D Spending
2007-2011
Table 4-23: Bristol-Myers Squibb's Late Stage Product Pipeline
Table 4-23: Bristol-Myers Squibb's Late Stage Product Pipeline
Figure 4-22: Bristol-Myers' Late Stage Product Pipeline by Therapeutic Area
Table 4-24: Takeda's Total Company Revenue* and R&D Spending 2007-2011
Table 4-25: Takeda Pharmaceutical's Late Stage Product Pipeline
Figure 4-24: Takeda Pharmaceutical's Late Stage Product Pipeline by
Therapeutic Area
Table 4-26: TEVA's Total Company Revenue and R&D Spending 2007-2011
Table 4-27: TEVA's Late Stage Product Pipeline
Figure 4-26: TEVA's Late Stage Product Pipeline by Therapeutic Area
Table 4-28: Amgen's Total Company Revenue and R&D Spending 2007-2011
Table 4-29: Amgen's Late Stage Product Pipeline
Figure 4-28: Amgen's Late Stage Product Pipeline by Therapeutic Area
Table 4-30: Boehringer Ingelheim's Total Company Revenue and R&D Spending
2007-2011
Table 4-31: Boehringer Ingelheim's Late Stage Product Pipeline
Figure 4-30: Boehringer Ingelheim's Late Stage Product Pipeline by
Therapeutic Area
Table 4-32: Bayer's Total Company Revenue and R&D Spending 2007-2011
Table 4-33: Bayer's Late Stage Product Pipeline
Figure 4-32: Bayers' Late Stage Product Pipeline by Therapeutic Area
Table 4-34: Novo Nordisk's Total Company Revenue and R&D Spending 2007-2011
Table 4-35: Novo Nordisk's Late Stage Product Pipeline
Figure 4-34: Novo Nordisk's Late Stage Product Pipeline by Therapeutic Area
Table 4-36: Astellas' Total Company Revenue and R&D Spending 2007-2011
Table 4-37: Astellas' Late Stage Product Pipeline
Figure 4-36: Astellas' Late Stage Product Pipeline by Therapeutic Area
Table 4-38: Daiichi Sankyo's Total Company Revenue and R&D Spending
2007-2011
Table 4-39: Daiichi Sankyo's Late Stage Product Pipeline
Figure 4-38: Daiichi Sankyo's Late Stage Product Pipeline by Therapeutic
Area
Table 4-40: Otsuka Holding's Total Company Revenue and R&D Spending
2007-2011
Table 4-41: Otsuka Pharmaceutical's Late Stage Product Pipeline
Figure 4-40: Otsuka Pharmaceutical's Late Stage Product Pipeline by
Therapeutic Area
CHAPTER FIVE: COMPANIES OF INTEREST
Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2011 Sales
Table 5-2: Merck KGaA's Late Stage Product Pipeline
Table 5-3: Gilead Sciences' Late Stage Product Pipeline
Table 5-4: Eisai's Late Stage Product Pipeline
Table 5-5: Celgene's Late Stage Product Pipeline
Table 5-6: Mitsubishi Tanabe's Late Stage Product Pipeline
Table 5-7: Allergan's Late Stage Product Pipeline
Table 5-8: Forest Laboratories' Late Stage Product Pipeline
Table 5-9: UCB Pharma's Late Stage Product Pipeline
Table 5-10: Dainippon Sumitomo's Late Stage Product Pipeline
Table 5-11: Shire's Late Stage Product Pipeline
Table 5-12: Biogen Idec's Late Stage Product Pipeline
Table 5-13: Hospira's Late Stage Product Pipeline
Table 5-14: Lundbeck's Late Stage Product Pipeline
Table 5-15: Kyowa Kirin's Late Stage Product Pipeline
Table 5-16: Menarini's Late Stage Product Pipeline
Table 5-17: Valeant's Late Stage Product Pipeline
Table 5-18: Shionogi's Late Stage Product Pipeline
Table 5-19: Actelion's Late Stage Product Pipeline
Table 5-20: Ono Pharmaceutical's Late Stage Product Pipeline
Table 5-21: Santen's Late Stage Product Pipeline
Table 5-22: Taisho's Late Stage Product Pipeline
CHAPTER SIX: MARKET FORECAST
Table 6-1: Top Biopharmaceutical Companies, 1-50 by 2011 Sales
Table 6-1: (Continued): Top Pharmaceutical/Biopharmaceutical Companies,
1-50 by 2011 Sales
Table 6-2: Company Pipelines by Total Late Stage Development Projects
(Top 20 Companies by Revenues)
Figure 6-1: Company Pipelines by Total Late Stage Development Projects
(Top 20 Companies by Revenues)
Table 6-3: Global Pharmaceutical Market Value by Therapeutic Segment,
2005-2010
Figure 6-2: Global Pharmaceutical Market Value by Therapeutic Segment,
2005-2010
Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2010
vs. 2011
Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment,
2010 vs. 2011
Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment,
2016 - based on late stage development projects evaluated
Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment,
2016 - based on late stage development projects evaluated
Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment,
2016 - Potential Impact from Late-Stage Development
Figure 6-6: Global Pharmaceutical Market Forecast by, 2016 - Potential
Impact from Late-Stage Development
Table 6-6: Top 5 Biotechnology Companies*, 2011 Sales
Table 6-7: Top 10 Biotechnology and Pharmaceutical Products, by 2011
Revenues
Figure 6-7: Top 10 Biotechnology and Pharmaceutical Products, by 2011
Revnues
Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016 published by Kalorama Information in August 3, 2012. This report consists of 220 Pages and the price starts from US $ 2500.
